Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data

about

Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care.Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.

P2860

Q47157022-BC5AFE46-2636-42EB-B413-1F9AB8A31655 Q48136341-2D50166E-E64D-4EDE-9684-602C64E94D57

P2860

Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data

Item

http://www.wikidata.org/entity/Q35937632

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Dose Escalation and Healthcare ...... An Analysis of Real-World Data

@ast

Dose Escalation and Healthcare ...... An Analysis of Real-World Data

@en

type

Item

label

Dose Escalation and Healthcare ...... An Analysis of Real-World Data

@ast

Dose Escalation and Healthcare ...... An Analysis of Real-World Data

@en

prefLabel

Dose Escalation and Healthcare ...... An Analysis of Real-World Data

@ast

Dose Escalation and Healthcare ...... An Analysis of Real-World Data

@en

P1476

Dose Escalation and Healthcare ...... An Analysis of Real-World Data

@en

P2093

Eilish McCann

http://www.w3.org/2001/XMLSchema#string

Eric Yu

http://www.w3.org/2001/XMLSchema#string

Sumesh Kachroo

http://www.w3.org/2001/XMLSchema#string

P2860

Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

P304

e0149692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0149692

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christopher M. Black

P577

2016-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26919745

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

P932

4768958

http://www.w3.org/2001/XMLSchema#string

Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data

about

P2860

P2860

Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932